Division Staff Contacts
NIGMS Funding Opportunities
NIGMS Funding Policies
NIGMS Twitter Feed
The NIGMS Biomedical Technology Development (BTDD) program has two goals:
Technology optimization is achieved through collaborations between Technology Development Projects (TDPs) and Driving Biomedical Projects (DBPs). Working iteratively with test bed DBPs, the TDPs develop and improve technologies by addressing challenges in a range of biomedical research problems. Technology dissemination is accomplished through Community Engagement (CE) activities that communicate the proposed technologies to the broad research community through training and publicity. Collaboration and Service Projects (CSPs), optional components of Community Engagement, provide access to the technology’s more mature capabilities.
NIGMS encourages investigators to propose BTDD Centers that focus on any of the biomedical technology research areas within the NIGMS mission.
Technologies of interest include, but are not limited to, one or combinations of the following: spectroscopy, microscopy, imaging, structural biology, molecular biology, cell manipulation, synthetic chemical biology, high throughput and analytical biochemistry, computational methods, molecular modeling, modeling of biological processes and data science.
The current BTDD program Funding Opportunity Announcement is
PAR-20-104: Biomedical Technology Development and Dissemination Center (RM1 - Clinical Trial Not Allowed). Potential applicants are strongly advised to contact NIGMS staff at least 10 weeks prior to the application due date to discuss the suitability of a proposed project for the NIGMS BTDD Program. Projects that require significant technology development fall outside of the scope of this program but may be appropriate for NIGMS
Technology Development Program (R21 or R01). Prospective applicants with mature technologies that are ready for a user resource may consider applying for the NIGMS
National and Regional Resources (R24) or the NIGMS Mature Synchrotron Resources (P30).
Christina Liu, Ph.D. PEProgram DirectorDivision of Biophysics, Biomedical Technology, and Computational BiosciencesNational Institute of General Medical SciencesNational Institutes of Health45 Center Drive MSC 6200Bethesda, MD 20892-6200
BTDD Grant Number:
RM1-GM144227Principal Investigator: Ryan A. Mehl, Ph.D.Genetic Code Expansion (GCE) technology – the engineering of cellular translation to express proteins containing non-canonical amino acids – provides unprecedented ways to probe and manipulate macromolecular structure and function, analyze protein malfunctions in disease, engineer bioanalytical tools, and create precision biotherapeutics. The GCE4All Center's mission is to optimize and extend existing GCE technologies to enable facile use by non-specialists and broadly disseminate them via widespread education, effective training, and sustainable access so that powerful GCE approaches become standard widely-used biomedical research tools.
Connect With Us: